(26) evaluated the efficacy and safety of Pembrolizumab (a PD-1 inhibitor) in patients with advanced recurrent ovarian cancer, and found that the expression level of PD-L1 was related to the efficacy. Here, CD274 is linked to ovarian carcinoma.